Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sevuparin sodium + atovaquone + proguanil
- Development stage
- Discontinued
- Lead developer
- Modus Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination of three agents: sevuparin sodium, atovaquone, and proguanil. Atovaquone and proguanil are antimalarial drugs used together to treat and prevent malaria caused by *Plasmodium falciparum*. Atovaquone inhibits the mitochondrial electron transport chain in the parasite, while proguanil acts as a biguanide that enhances the effect of atovaquone on mitochondrial membrane potential; its metabolite cycloguanil also inhibits dihydrofolate reductase but this is not central to their synergy[1][6]. Sevuparin sodium is an experimental drug being studied as an adjunctive therapy for severe malaria; it is a modified heparinoid designed to block sequestration of infected red blood cells in microvasculature, potentially improving outcomes when combined with standard antimalarial therapies[4]. The triple combination has been investigated for improved efficacy against severe or complicated malaria.
- Brand names
- Malarone
- Other names
- atovaquone and proguanil hydrochloridesevuparin/DF02
02
Targets
PfEMP1 (Plasmodium falciparum erythrocyte membrane protein 1)DHFR (Dihydrofolate reductase)bc1 complex (Cytochrome bc1 complex (plasmodium))
Beyond the preview
Go deeper on sevuparin sodium + atovaquone + proguanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sevuparin sodium + atovaquone + proguanil.